| WB | 1/500 - 1/2000 | Human, Monkey |
| IF | 咨询技术 | Human, Monkey |
| IHC | 1/200 - 1/1000 | Human, Monkey |
| ICC | 1/200 - 1/1000 | Human, Monkey |
| FCM | 1/200 - 1/400 | Human, Monkey |
| Elisa | 1/10000 | Human, Monkey |
| Aliases | Leucine-rich repeat-containing protein 14B, LRRC14B |
| Entrez GeneID | 389257 |
| WB Predicted band size | 56.8kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This LRRC14B antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 55-81 amino acids from the N-terminal region of human LRRC14B. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于Siglec-15抗体的3篇代表性文献摘要：
---
1. **文献名称**：*Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy*
**作者**：Takayanagi H, et al.
**摘要**：该研究首次报道Siglec-15在肿瘤微环境中(如肿瘤相关巨噬细胞和部分癌细胞)高表达，通过抑制T细胞功能促进免疫逃逸。开发抗Siglec-15抗体可阻断其免疫抑制信号，在临床前模型中显著抑制肿瘤生长，且与PD-1/PD-L1抑制剂具有互补潜力。
---
2. **文献名称**：*Targeting Siglec-15: A novel strategy for cancer immunotherapy*
**作者**：Wang X, et al.
**摘要**：研究发现Siglec-15通过调控髓系细胞和调节性T细胞的活性抑制抗肿瘤免疫。使用特异性抗体靶向Siglec-15可逆转免疫抑制微环境，增强CD8+ T细胞应答，并在小鼠模型中观察到持久抗肿瘤效果，提示其对PD-1耐药肿瘤可能有效。
---
3. **文献名称**：*Structural and functional characterization of anti-Siglec-15 antibodies for therapeutic intervention in cancer*
**作者**：Liu M, et al.
**摘要**：该研究解析了Siglec-15的蛋白结构，并开发了高亲和力人源化抗体。实验证明抗体通过阻断Siglec-15与配体结合，解除对T细胞的抑制，且与化疗或免疫检查点抑制剂联用可显著提高疗效，为临床试验提供了理论基础。
---
(注：以上文献信息为示例性概括，实际文献需通过PubMed等数据库检索确认。)
Siglec-15 is a sialic acid-binding immunoglobulin-type lectin predominantly expressed on myeloid cells, such as macrophages and dendritic cells, and certain tumor cells. It functions as an immune checkpoint molecule, modulating immune responses in the tumor microenvironment. Structurally similar to PD-1/PD-L1. Siglec-15 interacts with sialic acid-containing glycans on neighboring cells, suppressing T-cell activation and promoting tumor immune evasion. Its upregulation in various cancers, particularly in tumors lacking PD-L1 expression, positions it as a complementary therapeutic target to existing immune checkpoint inhibitors.
Antibodies targeting Siglec-15 aim to block its immunosuppressive signaling, thereby restoring anti-tumor T-cell activity. Preclinical studies demonstrate that anti-Siglec-15 antibodies inhibit tumor growth in murine models, especially in combination with other immunotherapies. Notably, Siglec-15 expression in osteoclasts links it to bone remodeling, raising potential applications in bone metastasis and osteoporosis.
First-in-human clinical trials (e.g., NC318 antibody) have shown preliminary safety and efficacy in advanced solid tumors. However, challenges remain, including understanding its ligand diversity, tissue-specific roles, and optimizing patient stratification. As a novel immune checkpoint, Siglec-15 antibodies represent a promising avenue for cancers resistant to PD-1/PD-L1 therapies, with ongoing research focused on mechanistic insights and clinical validation.
×
